Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer

IF 2.3 3区 医学 Q3 ONCOLOGY
Vivek Narayan , Miraj Y. Patel , Siguroli Teitsson , Lisa Rosenblatt , Xin Yin , Irina Pivneva , Sophie Gao , Manasvi Sundar , Keith A. Betts
{"title":"Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer","authors":"Vivek Narayan ,&nbsp;Miraj Y. Patel ,&nbsp;Siguroli Teitsson ,&nbsp;Lisa Rosenblatt ,&nbsp;Xin Yin ,&nbsp;Irina Pivneva ,&nbsp;Sophie Gao ,&nbsp;Manasvi Sundar ,&nbsp;Keith A. Betts","doi":"10.1016/j.clgc.2024.102188","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>There is limited real-world data regarding subsequent treatment utilization and clinical outcomes following initial androgen receptor pathway inhibitor (ARPI) exposure for the treatment of advanced prostate cancer. This study aimed to address this evidence gap.</p></div><div><h3>Methods</h3><p>Electronic health records during 01/01/2013-07/31/2022 from Flatiron Health were used to identify adults with mCRPC, who had prior exposure to ARPIs (irrespective of the setting) and ≥1 post-ARPI line of therapy (LOT) in the mCRPC setting (index therapy: the first eligible LOT in the mCRPC setting). Treatment patterns and survival outcomes following the initiation of index therapy were reported.</p></div><div><h3>Results</h3><p>Among 804 ARPI-experienced mCRPC patients, 459 patients (57.1%) received another ARPI as their index therapy and 192 (23.9%) received chemotherapy as their index therapy. In the overall population, median time on the index therapy and median time from index therapy to next therapy were 4.1 and 6.2 months, respectively. Median overall survival and radiographic progression-free survival from the initiation of index therapy were 15.1 and 7.0 months, respectively.</p></div><div><h3>Conclusions</h3><p>In this real-world analysis, more than half of patients attempted at least 1 additional ARPI in the mCRPC setting, despite prior treatment with ARPIs. The short treatment duration and survival time highlight the unmet need for additional, effective therapies that may improve clinical outcomes in this population.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102188"},"PeriodicalIF":2.3000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1558767324001599/pdfft?md5=f083c4da3f437fcaba69eeb9c690a0b9&pid=1-s2.0-S1558767324001599-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324001599","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

There is limited real-world data regarding subsequent treatment utilization and clinical outcomes following initial androgen receptor pathway inhibitor (ARPI) exposure for the treatment of advanced prostate cancer. This study aimed to address this evidence gap.

Methods

Electronic health records during 01/01/2013-07/31/2022 from Flatiron Health were used to identify adults with mCRPC, who had prior exposure to ARPIs (irrespective of the setting) and ≥1 post-ARPI line of therapy (LOT) in the mCRPC setting (index therapy: the first eligible LOT in the mCRPC setting). Treatment patterns and survival outcomes following the initiation of index therapy were reported.

Results

Among 804 ARPI-experienced mCRPC patients, 459 patients (57.1%) received another ARPI as their index therapy and 192 (23.9%) received chemotherapy as their index therapy. In the overall population, median time on the index therapy and median time from index therapy to next therapy were 4.1 and 6.2 months, respectively. Median overall survival and radiographic progression-free survival from the initiation of index therapy were 15.1 and 7.0 months, respectively.

Conclusions

In this real-world analysis, more than half of patients attempted at least 1 additional ARPI in the mCRPC setting, despite prior treatment with ARPIs. The short treatment duration and survival time highlight the unmet need for additional, effective therapies that may improve clinical outcomes in this population.

雄激素受体通路抑制剂治疗经验丰富的转移性阉割耐药前列腺癌患者的治疗模式和生存结果
背景有关初次接触雄激素受体途径抑制剂(ARPI)治疗晚期前列腺癌后的后续治疗利用率和临床结果的真实世界数据十分有限。本研究旨在填补这一证据空白。方法利用Flatiron Health公司2013年1月1日至2022年7月31日期间的电子健康记录来识别mCRPC成人患者,这些患者之前曾接触过ARPIs(无论在哪种情况下),并且在mCRPC情况下ARPI治疗线(LOT)后≥1次(指数治疗:在mCRPC情况下符合条件的首次LOT)。结果在804名接受过ARPI治疗的mCRPC患者中,有459名患者(57.1%)接受了另一种ARPI作为其指标疗法,有192名患者(23.9%)接受了化疗作为其指标疗法。在总体人群中,接受初始治疗的中位时间和从初始治疗到下一次治疗的中位时间分别为4.1个月和6.2个月。结论在这项真实世界分析中,尽管之前已接受过 ARPIs 治疗,但仍有一半以上的患者在 mCRPC 环境中尝试了至少一种额外的 ARPI。较短的治疗时间和存活时间凸显了对其他有效疗法的需求尚未得到满足,而这些疗法可能会改善这一人群的临床预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical genitourinary cancer
Clinical genitourinary cancer 医学-泌尿学与肾脏学
CiteScore
5.20
自引率
6.20%
发文量
201
审稿时长
54 days
期刊介绍: Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信